Control fund research profile
Kedaara is an India-focused private-equity manager combining financial investing with senior operating expertise. Its public strategy is growth-oriented strategic and minority investing in secular sectors, with value creation built into the investment model.
At a glance
Research profile
Open a section to inspect the evidence. The first view starts with the investment point of view; the rest stays quiet until you need it.
Investment lens
Kedaara Capital uses a control / co-control mid-market approach across Consumer, fin services, health, industrials.
Current evidence
Kedaara announced the 2025 $60 million Juspay Series D led investment and its 2024 Dairy Day investment; the FY24 ESG report identifies 26 investments and names current portfolio companies including Perfios, K12, Ajax, Oasis Fertility, ASG Eye Hospital, Lenskart, Dairy Day, Purplle, Vishal Mega Mart, Aavas, Spandana, Veritas, Care Health and Avanse.
Strategy
Control / co-control mid-market
Sector focus
Consumer, fin services, health, industrials
AIF structure context
Indian private equity, growth, buyout and many real-asset strategies are commonly structured as Category II AIFs. Verify the specific vehicle and registration before investing.
Current signal
Kedaara announced the 2025 $60 million Juspay Series D led investment and its 2024 Dairy Day investment; the FY24 ESG report identifies 26 investments and names current portfolio companies including Perfios, K12, Ajax, Oasis Fertility, ASG Eye Hospital, Lenskart, Dairy Day, Purplle, Vishal Mega Mart, Aavas, Spandana, Veritas, Care Health and Avanse.
Investor questions
Kedaara Capital is covered in Rupeia's private equity research universe. The current public record describes the strategy as Control / co-control mid-market, with a sector focus of Consumer, fin services, health, industrials. The profile should be read with the linked source trail and Typical route: Category II AIF context.
The profile displays only company or asset names attributable to Kedaara Capital in the reviewed public sources: Lenskart, Purplle, AU Small Finance Bank, Perfios, Vijaya Diagnostics, Ami Lifesciences, Ajax Engineering, Neurealm. It does not represent a complete current portfolio unless the manager has published one.
Kedaara’s disclosed exits include Parksons Packaging and Manjushree Technopack, while its press archive shows active investments in companies such as Porter, Perfios, Juspay and Impetus. The public record does not disclose fund-level IRR or DPI. These signals are not a substitute for fund- and vintage-specific net performance, realised distributions and audited or administrator-supported reporting.
Public fund size: Kedaara says the investment team manages or advises approximately $5.6B in AUM on its strategy page; the reviewed sources do not establish a single current vehicle size.. Public terms or access information: Growth-oriented strategic and minority investments in Indian businesses, supported by operating partners; public sources do not provide a uniform cheque or reserve range.. Current fees, minimum commitment and availability must be confirmed for the exact named vehicle in its fund documents.
The current source record names Manish Kejriwal, Sunish Sharma, Nishant Sharma. Verify current roles, departures, attribution and key-person provisions before relying on the team history for a new commitment.
Review entry valuation, leverage, governance rights, concentration, execution of the value-creation plan and exit timing. The current open diligence point is: Fund IV deployment and transaction-level terms require periodic re-verification; fund-level returns are not publicly disclosed..
2025: Kedaara announced the 2025 $60 million Juspay Series D led investment and its 2024 Dairy Day investment; the FY24 ESG report identifies 26 investments and names current portfolio companies including Perfios, K12, Ajax, Oasis Fertility, ASG Eye Hospital, Lenskart, Dairy Day, Purplle, Vishal Mega Mart, Aavas, Spandana, Veritas, Care Health and Avanse.
Next step
Share the allocation question, ticket size, liquidity constraints and existing exposure. Rupeia can determine whether this profile needs a deeper decision-support brief.